COVID-19 Vaccines: Placebo Crossover May Depend Upon Number Of Doses, Allocation Strategy

 
• By Sue Sutter

Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.  

Editorial use only - ARCADIA, CA - MAR 20: Horses break from the gate in an allowance race at Santa Anita Park on Mar 20, 2010 in Arcadia, CA
Once the first COVID-19 vaccines out of the gate become available, clinical trials of earlier-stage candidates might look different. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers